Sana Biotechnology (SANA) director granted 90,000 stock options at $2.96 strike

Rhea-AI Filing Summary

Sana Biotechnology director Alise Reicin received a grant of stock options covering 90,000 shares of common stock. The options have an exercise price of $2.96 per share and will expire on June 3, 2036.

The option vests in full as to all 90,000 underlying shares on the earlier of June 4, 2027 or immediately before Sana Biotechnology’s 2027 annual meeting of stockholders, as long as Reicin continues providing service to the company through that date. Following this grant, she holds options on 90,000 shares directly.

Insights

Equity compensation analyst

Director received a standard time-based option grant for 90,000 shares.

Sana Biotechnology awarded director Alise Reicin stock options for 90,000 shares at an exercise price of $2.96 per share. The options are a form of equity compensation rather than an open-market purchase or sale.

The grant vests 100% on the earlier of June 4, 2027 or immediately prior to the 2027 annual stockholder meeting, conditioned on continuous service. This creates a clear retention incentive aligned with the company’s medium-term timeline.

Because this is a routine director grant with no associated market sale or purchase, it is generally viewed as an administrative compensation event rather than a trading signal. Future company filings may show additional grants or exercises that change Reicin’s overall equity exposure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider REICIN ALISE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Key Figures

Option grant size: 90,000 shares Exercise price: $2.96 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 90,000 shares Stock options awarded to director Alise Reicin

Exercise price $2.96 per share Stock option strike price

Expiration date June 3, 2036 Option term end date

Vesting date Earlier of June 4, 2027 or 2027 annual meeting Full vesting condition with continuous service

Post-transaction derivative holdings 90,000 options Total options held after grant

Key Terms

Stock Option (Right to Buy), exercise price, vests and becomes exercisable, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

annual meeting of stockholders financial

"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."

continuous service financial

"provided that the reporting person provides continuous service to Sana through such date"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/05/2026 - 04:38 PM Accepted by SEC EDGAR 06/05/2026 - 04:38 PM Learn about SEC filing dates

FAQ

What did Sana Biotechnology (SANA) director Alise Reicin receive in this Form 4?

Alise Reicin received a stock option grant for 90,000 shares of Sana Biotechnology common stock. The options are a compensation award, not an open-market purchase, and give her the right to buy shares at a fixed exercise price if they vest and are exercised.

What is the exercise price of Alise Reicin’s Sana (SANA) stock options?

The stock options have an exercise price of $2.96 per share. This means Reicin can buy Sana Biotechnology common stock at $2.96 for each optioned share if she chooses to exercise the options after they vest and before they expire.

When do Alise Reicin’s Sana Biotechnology (SANA) options vest?

The options vest 100% on the earlier of June 4, 2027 or immediately before Sana Biotechnology’s 2027 annual stockholder meeting. Vesting requires that Reicin continue providing service to the company through that vesting date as described in the filing footnote.

When do the stock options reported by Sana (SANA) director Alise Reicin expire?

The options expire on June 3, 2036. After that expiration date, any unexercised options become worthless, so Reicin would need to exercise vested options before that date if she wishes to acquire Sana Biotechnology common shares through this grant.

How many Sana Biotechnology (SANA) options does Alise Reicin hold after this transaction?

After this transaction, Reicin holds options covering 90,000 shares of Sana Biotechnology common stock directly. This figure reflects the total derivative securities reported in the Form 4 as of the transaction date, based on the filing’s post-transaction holdings field.

Is Alise Reicin’s Sana (SANA) Form 4 transaction a stock purchase or sale?

The Form 4 reports an acquisition of stock options as a compensation grant, not a market purchase or sale of common shares. The transaction code A indicates a grant or award, and no open-market buying or selling of Sana Biotechnology stock is disclosed here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REICIN ALISE

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Alise Reicin	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)